APA (7th ed.) Citation

CC, Y., CS, F., LL, C., KV, C., CH, H., CC, C., . . . TS, H. (2026). Preclinical evaluation of rBCG-h12: An engineered Bacillus Calmette-Guérin with an enhanced activity against bladder and pancreatic cancers. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-026-04441-9

Chicago Style (17th ed.) Citation

CC, Yeh, et al. "Preclinical Evaluation of RBCG-h12: An Engineered Bacillus Calmette-Guérin with an Enhanced Activity Against Bladder and Pancreatic Cancers." Cancer Immunology, Immunotherapy : CII 2026. https://doi.org/10.1007/s00262-026-04441-9.

MLA (9th ed.) Citation

CC, Yeh, et al. "Preclinical Evaluation of RBCG-h12: An Engineered Bacillus Calmette-Guérin with an Enhanced Activity Against Bladder and Pancreatic Cancers." Cancer Immunology, Immunotherapy : CII, 2026, https://doi.org/10.1007/s00262-026-04441-9.